百奥赛图-B午前涨超6% IDE034首例患者给药触发500万美元里程碑款项

Core Viewpoint - The stock of Baiaotech-B (02315) has risen over 6%, currently trading at 53.35 HKD with a transaction volume of 28.48 million HKD, following the announcement of a significant milestone in its collaboration with IDEAYA on the ADC IDE034 [1][4]. Group 1: Company Developments - IDEAYA has announced the completion of the first patient enrollment in the Phase I dose escalation/expansion clinical trial for its investigational PTK7/B7H3 bispecific TOP1 antibody-drug conjugate (ADC) IDE034 [1][4]. - The first patient dosing of IDE034 will trigger a milestone payment of 5 million USD from IDEAYA to Baiaotech, as per their signed option and licensing agreement [1][4]. - IDE034 is a potentially first-in-class dual-target B7H3/PTK7 TOP1 ADC, developed independently by Baiaotech and licensed to IDEAYA in July 2024 [1][4]. Group 2: Regulatory Milestones - The project received FDA approval for clinical trials in December of the previous year, marking a significant regulatory milestone for both companies [1][4]. - The IND approval signifies an important step in the collaboration, laying the groundwork for the subsequent clinical development of IDE034 [1][4]. - This development highlights Baiaotech's technical capabilities in the discovery and development of bispecific ADCs [1][4].